Consensus ORIC Pharmaceuticals, Inc.

Stocks

ORIC

US68622P1093

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 24/10/2026 am IST			5-day change	1st Jan Change
13.17 ^USD	-3.37%		+6.64%	+61.00%

23/10	ORIC Pharmaceuticals, Inc. - Special Call
23/10	Oric Pharmaceuticals, Inc. Presents Potential Best-In-Class Data for Enozertinib in First-Line Nsclc Patients with Egfr Atypical Mutations At Esmo Congress 2026 and Plans to Advance Enozertinib into Global Phase 3 Trial	CI

Evolution of the Average Target: ORIC Pharmaceuticals, Inc.

Evolution of the Target Price: ORIC Pharmaceuticals, Inc.

Changes in Analyst Recommendations: ORIC Pharmaceuticals, Inc.

84.AVSeYSoiMzBZnWw2Vv4BxpNwaOt1rFM5VOnE9mzkzyc.aybKBGhpX0MApRpeMb1G6_g0L5oEygtOC6b3xh-zhRUsIO8wWltrWh3WXA~6ff147e74cf7910595228db113aab8f5

Analysts' recommendations: ORIC Pharmaceuticals, Inc.

05/10	Leerink Partners Initiates ORIC Pharmaceuticals at Outperform With $26 Price Target	MT
23/09	BTIG Initiates ORIC Pharmaceuticals at Buy With $26 Price Target	MT
01/04	Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating	MT
07/01	Piper Sandler Initiates ORIC Pharmaceuticals Inc at Overweight With $22 Price Target	MT
14/11	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $15 From $12, Maintains Outperform Rating	MT
06/25/06	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating	MT
31/24/31	JonesTrading Initiates ORIC Pharmaceuticals at Buy With $17 Price Target	MT
31/24/31	Wells Fargo Initiates ORIC Pharmaceuticals at Overweight With $20 Price Target	MT
06/24/06	Stifel Nicolaus Initiates Coverage on ORIC Pharmaceuticals With Buy Rating, $20 Price Target	MT
13/24/13	Oppenheimer Adjusts ORIC Pharmaceuticals Price Target to $15 From $17, Maintains Outperform Rating	MT
27/24/27	JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating	MT
21/24/21	HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating	MT
12/24/12	Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating	MT
01/24/01	Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating	MT
26/24/26	Cantor Fitzgerald Initiates ORIC Pharmaceuticals at Overweight Rating	MT
13/23/13	HC Wainwright Trims Price Target on ORIC Pharmaceuticals to $15 From $16, Keeps Buy Rating	MT
12/23/12	Wedbush Lowers ORIC Pharmaceuticals' PT to $12 From $14, Pushes Out Launch Assumption for ORIC-533; Keeps Outperform Rating	MT
26/23/26	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $16 From $13, Maintains Buy Rating	MT
24/23/24	JPMorgan Adjusts ORIC Pharmaceuticals' Price Target to $17 From $14, Maintains Overweight Rating	MT
23/23/23	Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $15 From $13, Maintains Buy Rating	MT
22/23/22	Wedbush Starts ORIC Pharmaceuticals at Outperform With $14 PT, Says Expanding Pipeline Provides Future Potential Growth Opportunities	MT
16/23/16	Baird Adjusts Price Target on ORIC Pharmaceuticals to $27 From $15, Keeps Outperform Rating	MT
15/23/15	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $13 From $14, Keeps Buy Rating	MT
10/23/10	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $14 From $16, Keeps Buy Rating	MT
05/23/05	Citigroup Adjusts Price Target on ORIC Pharmaceuticals to $8 From $9, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ORIC PHARMACEUTICALS, INC.					+58.79%
	WUXI APPTEC CO., LTD.					+35.78%
	ARGENX SE					+28.93%
	LONZA GROUP AG					+10.89%
	IQVIA HOLDINGS INC.					+8.75%
	BEONE MEDICINES AG					+14.18%
	REVOLUTION MEDICINES, INC.					+37.21%
	CELLTRION, INC.					+37.85%
	WUXI BIOLOGICS (CAYMAN) INC.					+32.7%
	GENMAB A/S					+4.59%
	Average					+26.97%
	Weighted average by Cap.					+23.95%